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Abstract The presumed protective e¡ect of folic acid on the
pathogenesis of cardiovascular, hematological and neurological
diseases and cancer has been associated with the antioxidant
activity of folic acid. Peroxynitrite (PON) scavenging activity
and inhibition of lipid peroxidation (LPO) of the physiological
forms of folate and of structurally related compounds were
tested. It was found that the fully reduced forms of folate,
i.e. tetrahydrofolate (THF) and 5-methyltetrahydrofolate
(5-MTHF), had the most prominent antioxidant activity. It ap-
peared that their protection against LPO is less pronounced
than their PON scavenging activity. The antioxidant activity
of these forms of folic acid resides in the pterin core, the anti-
oxidant pharmacophore is 4-hydroxy-2,5,6-triaminopyrimidine.
It is suggested that an electron donating e¡ect of the 5-amino
group is of major importance for the antioxidant activity of
4-hydroxy-2,5,6-triaminopyrimidine. A similar electron donat-
ing e¡ect is probably important for the antioxidant activity of
THF and 5-MTHF.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Folates function as cofactors in the transfer and utilization
of one carbon groups. This plays a key role in the biosynthesis
of purines and pyrimidines and regeneration of methionine
[1]. Folic acid (FA) is made up of a pterin moiety (purine
and pyrazine fused together) that is linked to the side chain
containing p-aminobenzoic acid (pteroic acid) and glutamic
acid (Fig. 1). FA exists in lactam and lactim tautomeric forms.
The lactam form has a 4-OH moiety on the purine-type ring
(Fig. 1). FA is in vivo reduced to dihydrofolate (DHF) and
subsequently to tetrahydrofolate (THF). THF is enzymati-
cally converted into 5-methyltetrahydrofolate (5-MTHF), the
actual active form [1].
Epidemiological studies have shown that FA supplementa-
tion can signi¢cantly reduce the risk of cardiovascular and
hematological diseases [2,3], neurological and neuropsychiat-
ric disorders [4,5], neural tube defects [6] and cancer including
cervical, lung, brain, pancreatic, colorectal and breast cancer
[7,8]. The production of reactive oxygen species, reactive
chlorine species and reactive nitrogen species is implicated in
these pathologies. Therefore, the antioxidant activity of FA
has been suggested to be involved in the presumed e¡ect of
FA on health [9,10]. There is no consensus about the free
radical scavenging activity of FA. One study [10] suggested
that the 4-OH group on the pterin ring has an important role.
Another study [11] indicated that the side chain, i.e. N-(p-
aminobenzoyl)-L-glutamic acid, is more important, since the
products formed by nitration of FA were identi¢ed as 10-
nitrofolate and 12-nitrofolate [11]. The present study was de-
signed to further examine the antioxidant activity of FA and
its physiological metabolites and to determine which part of
the molecule is important for this activity.
2. Materials and methods
2.1. Chemicals
FA, DHF, 2,4-diamino-6-hydroxypyrimidine, 4-hydroxy-2,5,6-tri-
aminopyrimidine and KO2 were obtained from Fluka Chemie (Buchs,
Switzerland). 2-Amino-4-hydroxypyrimidine, THF, 5-MTHF, 5,6,7,8-
tetrahydrobiopterin (BH4), leucopterin and dihydrorhodamine-123
(DHR-123) and 2,2P-azinobis(3-ethylbenzthiazoline-6-sulfonic acid
(ABTS) were obtained from Sigma Chemical Co. (St. Louis, MO,
USA). All other chemicals were of the highest grade of purity avail-
able.
2.2. Isolation of rat liver microsomes
Male Lewis rats, 200^250 g, were killed by decapitation. Micro-
somes were prepared according to Haenen and Bast [12] with a slight
modi¢cation. Livers were removed and homogenized (1:2 w/v) in ice-
cold phosphate bu¡er (50 mM, pH 7.4) containing 0.1 mM EDTA.
The homogenate was centrifuged at 10 000Ug for 30 min at 4‡C.
Subsequently, the supernatant was centrifuged at 65 000Ug for 60
min at 4‡C. The microsomal pellet was resuspended in the phosphate
bu¡er (2 g liver tissue/ml), corresponding to 1^1.3 mg protein/ml, and
stored at 380‡C. Storage of microsomes at 380‡C has no e¡ect on
the oxidation state of microsomes in the in vitro assay. Before use the
microsomes were thawed and diluted ¢ve-fold with ice-cold Tris^HCl
bu¡er (50 mM, pH 7.4) containing 150 mM KCl and washed twice
followed by centrifugation at 65 000Ug for 40 min at 4‡C. Finally, the
pellet was resuspended in 4 ml Tris^HCl bu¡er and then used.
2.3. Lipid peroxidation (LPO) assay
2.3.1. Incubation conditions. LPO assay was carried out according
to Haenen and Bast [12] with a minor modi¢cation. At 37‡C, 450 Wl
of Tris^HCl/KCl bu¡er was added to 250 Wl of microsomes, the ¢nal
concentration was 0.5 g liver tissue/ml. Hundred Wl of a solution
containing one of the test compounds was added to achieve the de-
sired concentration. A solution of ascorbate (125 Wl) was added giving
a ¢nal concentration of 0.2 mM. The reaction was started by adding
75 Wl of a freshly prepared ferrous sulfate solution giving a ¢nal con-
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centration of 10 WM. After 20 min incubation, the reaction was
stopped as described in Section 2.3.2. The e¡ects are expressed as
the concentration giving 50% inhibition of LPO (LPO IC50).
2.3.2. Spectral measurements. LPO was assayed by measuring
thiobarbituric acid (TBA)-reactive material [12]. The incubation mix-
ture (1 ml) was stopped by adding 2 ml of an ice-cold TBA^trichloro-
acetic acid^HCl^butylhydroxytoluene (BHT) solution. The mixture
was heated for 15 min at 90‡C and then centrifuged for 5 min. The
absorbance was determined at 535 nm vs. 600 nm. The TBA^tri-
chloroacetic acid^HCl^BHT solution was prepared by dissolving
41.6 mg TBA/10 ml trichloroacetic acid (16.8 w/v in 0.125 N HCl).
To 10 ml TBA^trichloroacetic acid^HCl 1 ml BHT (1.5 mg/ml etha-
nol) was added. The added chemicals did not interfere with the assay
in the concentrations used.
2.4. Synthesis of peroxynitrite (PON)
Potassium oxoperonitrate (ONOOK) was produced from the reac-
tion of solid KO2 with NO gas as described by Koppenol et al. [13].
Brie£y, the NO gas slowly £owed over the mixture of KO2 and quartz
sand, which was constantly stirred and kept on ice. The mixture
was poured into a cold potassium hydroxide solution. Addition of
manganese dioxide removes the hydrogen peroxide that results from
excess decomposition of potassium superoxide. The solution with
PON was obtained by ¢ltering o¡ the sand and manganese dioxide.
The concentration of PON was determined spectrophotometrically at
302 nm.
2.5. Oxidation of DHR-123
PON scavenging was measured by the oxidation of DHR-123 as
described by Kooy et al. [14]. In short, 100 Wl of the desired concen-
tration of the test compound was added to 0.9 ml of 100 mM phos-
phate bu¡er at 37‡C. The ¢nal concentration of DHR-123 in phos-
phate bu¡er was 5 WM. During mixing 10 Wl of PON (in 0.01 M
NaOH) was added giving a ¢nal concentration of 0.6 WM. The £uo-
rescent product, rhodamine-123, was measured by £uorescence detec-
tion with excitation and emission wavelengths of 500 and 536 nm,
respectively. The e¡ects are expressed as the concentration giving
50% inhibition of the oxidation of DHR-123 (PON IC50).
Fig. 1. The antioxidant activity of FA and its physiological metabolites measured by PON scavenging and inhibition of LPO. The activity is
expressed as the concentration of the compound that gives 50% scavenging of PON (IC50 PON) and the concentration that is needed to inhibit
50% of LPO (IC50 LPO). FA is made up of two parts, viz. a pterin moiety (A) and an N-(p-aminobenzoyl)-L-glutamic acid part (B). The num-
bering of the most important atoms is also shown in the chemical structure of FA. Values are presented as medianOhalf of the range of at
least three separate experiments.
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2.6. The trolox equivalent antioxidant capacity (TEAC) assay
The TEAC assay modi¢ed by Arts et al. [15] was used. ABTSc stock
solution was prepared by dissolving 30 mg ABTS in 7.8 ml of 2.46
mM potassium peroxodisulfate. The ABTSc stock solution was diluted
with 100 mM phosphate bu¡er (pH 7.4) to give an absorbance at 734
nm between 0.68 and 0.73 at 37‡C. The concentration of ABTSc was
determined using a molar extinction coe⁄cient of 1.5U104 M31
cm31. For measuring the antioxidant capacity, a ¢xed concentration
of the test compounds in this experiment, 5 WM, was mixed with
di¡erent concentrations (0^46 WM) of the ABTSc solution. Absor-
bance was monitored at 734 nm after 6 min incubation at 37‡C.
The total amount of ABTSc scavenged by the antioxidant, i.e. a in
the formula, was calculated using the exponential formula
y= a(13eð3bxÞ) (Sigma Plot, version 7). In this formula y is the reduc-
tion of the ABTSc concentration after 6 min and x is the initial ABTSc
concentration. The TEAC value is determined using the equation
TEACtest compound = a/(5U1.9), where 5 is the concentration of the
test compound in WM used in the experiment and 1.9 is the average
concentration of ABTSc that is scavenged per WM trolox.
3. Results
Fig. 1 gives an overview of the antioxidant activities of FA
and its physiological metabolites. The concentration of FA
needed to prevent the PON-mediated oxidation of DHR-123
by 50% (IC50 PON) is higher than 100 WM and the concen-
tration of FA needed to inhibit LPO by 50% (IC50 LPO) is
higher than 500 WM. Reduction of FA to DHF increased the
PON scavenging activity (IC50 PON=2.4 WM), whereas the
concentration needed to inhibit LPO by 50% was still above
500 WM. Reduction of DHF to THF resulted in a more than
three-fold increase in the ability to protect against LPO and
also the ability to scavenge PON was increased. The PON
scavenging activity of 5-MTHF compared to that of THF
was higher (the IC50 values were 0.9 WM and 1.5 WM, respec-
tively) and the protective e¡ect against LPO was lower (the
IC50 values were above 500 WM and 189 WM, respectively).
The TEAC values of THF and 5-MTHF were equivalent to
1.8O 0.1 and 0.7O 0.1 WM trolox, respectively (Fig. 2).
FA can be split into two parts, viz. an N-(p-aminobenzoyl)-
L-glutamic acid part and a pterin moiety. The IC50 of N-(p-
aminobenzoyl)-L-glutamic acid was higher than 500 WM for
either PON scavenging or inhibition of LPO (data not
shown). As shown in Fig. 3, the antioxidant activity of BH4
was comparable to that of THF (IC50 LPO=86O1 WM, IC50
PON=0.5O 0.2 WM). The antioxidant activity of 4-hydroxy-
2,5,6-triaminopyrimidine was also comparable to that of
THF. Removing the 5 amino group or the 5 and the 6 amino
groups of 4-hydroxy-2,5,6-triaminopyrimidine drastically re-
duced the antioxidant activity. Pterin also displayed no anti-
oxidant activity, whereas leucopterin has a moderate PON
scavenging activity.
4. Discussion
An antioxidant e¡ect of FA and its physiological metabo-
lites might be involved in some of the positive health e¡ects.
The rationale for the present study was to determine the anti-
oxidant activity of the various endogenous folates and to elu-
cidate which moiety of the molecule determines this activity.
FA has a poor antioxidant activity in PON scavenging and
LPO inhibition. Its physiological metabolites are more active.
Joshi et al. [10] reported that 500 WM of FA induced a 37%
inhibition of LPO, which corresponds to the protection
we found, i.e. IC50 LPOs 500 WM. Based on this partial
inhibition by a relatively high concentration, Joshi et al.
[10] speculated on a physiological relevance of FA as an anti-
oxidant. We think that the minor protective e¡ect of FA
on LPO is physiologically not relevant. The marginal antioxi-
dant e¡ect of FA is also seen from its poor PON scavenging
activity.
Reduction of FA to DHF results in a more prominent PON
scavenging activity than that of FA, whereas the IC50 for
inhibition of LPO is still higher than 500 WM. Further reduc-
tion to THF and conversion to 5-MTHF enhanced the PON
scavenging activity even more. The fully reduced forms, i.e.
THF and 5-MTHF, were the most active compounds in in-
hibiting LPO. 5-MTHF had a relatively lower activity in the
protection against LPO than THF (500 WM of 5-MTHF in-
duced 46% LPO inhibition), whereas the PON scavenging
activity of 5-MTHF was superior to that of THF. Compared
to other compounds, the protective e¡ect of the folates against
LPO seems less relevant than their PON scavenging activity.
For example, the £avonoid quercetin is much more potent in
inhibiting LPO (IC50 of quercetin = 9 WM) [16] than the fo-
lates, whereas its PON scavenging activity is in the same order
of magnitude (IC50 of quercetin = 0.53 WM) [17]
To determine the pharmacophore which is responsible for
the antioxidant activity of the reduced forms of FA, structur-
ally related compounds were tested. The minor importance of
the side chain for the antioxidant activity is demonstrated by
(i) the absence of antioxidant activity of N-(p-aminobenzoyl)-
L-glutamic acid, (ii) the large di¡erence in activity of the var-
ious folates which all contain the same side chain and (iii) the
antioxidant activity of BH4 (which lacks the side chain) which
is comparable to that of THF. Apparently, the antioxidant
activity resides in the pterin moiety. An optimal antioxidant
activity is achieved when the pterin ring is in its reduced form.
By comparing structurally related compounds (Fig. 3), it was
found that the antioxidant pharmacophore of the fully re-
duced form of folates, i.e. THF, is 4-hydroxy-2,5,6-triamino-
pyrimidine.
The potency of substituted phenols for PON scavenging
Fig. 2. Determination of the TEAC of THF and 5-MTHF. The re-
action of 5 WM THF (a) and 5 WM of 5-MTHF (b) with various
concentrations of ABTSc was assessed. The concentration of ABTSc
that is consumed by the antioxidant in 6 min is plotted against the
initial concentration of ABTSc. The TEAC of THF is 1.8O 0.1 and
that of 5-MTHF is 0.7 O 0.1.
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and protection against LPO is governed by the electron do-
nating e¡ect of the substituent [16,17]. The higher the electron
donating e¡ect, the higher the antioxidant activity. The elec-
tron donating e¡ect of a substituent depends on the nature as
well as the position of the substituent. For example, the ac-
tivity of a strong electron donating group, such as the hydrox-
yl group, on the ortho and para positions is much higher than
that on the meta position. This may explain the potent anti-
oxidant activity of catechol (hydroxyl group at the ortho po-
sition; IC50 LPO=10 WM, IC50 PON=2.7 WM) [16,17] and
hydroquinone (hydroxyl group at the para position; IC50
LPO=156 WM, IC50 PON=1.8 WM) [16,17] compared to
that of resorcinol (hydroxyl group at the meta position;
IC50 LPOs 1000 WM, IC50 PON=42.5 WM) [16,17]. For com-
parison, for phenol the IC50 LPO is s 1000 WM and the IC50
PON is 263 WM [16,17]. An amino group has an even higher
electron donating e¡ect than a hydroxyl group. For 2-amino-
phenol, the IC50 LPO is 5 O 0.5 WM and the IC50 PON is
0.6 O 0.1 WM. Similarly, the IC50 LPO of 4-aminophenol is
12 WM and the IC50 PON is 0.9 WM [16,17]. In analogy
with the di¡erence in activity due to the position of the sub-
stituent given above, it is suggested that the 5 amino group of
4-hydroxy-2,5,6-triaminopyrimidine is of major importance.
The location of this potent electron donating group at the
ortho position of the 4 hydroxyl group will boost the activity
of the aromatic hydroxyl group, and may explain the potent
activity of 4-hydroxy-2,5,6-triaminopyrimidine to a great ex-
tent.
Fig. 3. The antioxidant activity of 4-hydroxy-2,5,6-triaminopyrimidine and structurally related compounds measured by PON scavenging and
the inhibition of LPO. The activity is expressed as the concentration of the compound that gives 50% scavenging of PON (IC50 PON) and the
concentration that is needed to inhibit 50% of LPO (IC50 LPO). Values are presented as medianOhalf of the range of at least three separate
experiments.
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In leucopterin, the electron withdrawing e¡ect of the car-
bonyl groups next to the 5 and 6 amino groups will reduce the
electron donating e¡ect the 4-hydroxyl group receives. This
may explain the lower antioxidant activity of leucopterin com-
pared to 4-hydroxy-2,5,6-triaminopyrimidine and BH4.
A di¡erence in electron donating e¡ect may also explain the
higher PON scavenging activity of 5-MTHF compared to
THF. The methyl group at the 5 amino group in 5-MTHF
will slightly enhance the electron donating e¡ect of the 5 ami-
no group. Based on the TEAC, the number of radicals that
can be scavenged by 5-MTHF is lower than that of THF.
Possibly, this may explain the low activity of 5-MTHF in
the protection against LPO compared to that of THF. The
actual antioxidant e¡ect of folates in vivo might depend on
both reduction by the enzyme 5,10-methylenetetrahydrofolate
and consumption which is related to vitamin B12 and homo-
cysteine levels.
In conclusion, FA is a poor antioxidant. The more FA is
reduced, the higher its antioxidant activity becomes: THF and
5-MTHF are the folates with the most prominent antioxidant
activity. The antioxidant pharmacophore of THF and 5-
MTHF, i.e. 4-hydroxy-2,5,6-triaminopyrimidine, resides in
the pterin moiety. It is suggested that an electron donating
e¡ect of the 5 amino group is of major importance in the
antioxidant activity of 4-hydroxy-2,5,6-triaminopyrimidine.
A similar electron donating e¡ect is probably involved in
the antioxidant activity of THF and 5-MTHF.
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